The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.

Naoko Sueoka-AraganeChiho NakashimaHironori YoshidaNaohisa MatsumotoKentaro IwanagaNoriyuki EbiAkihiro NishiyamaKazuhiro YateraShoichi KuyamaMinoru FukudaSunao UshijimaHitomi UmeguchiDaijiro HaradaKosuke KashiwabaraTakayuki SuetsuguNobukazu FujimotoFumihiro TanakaHidetaka UramotoChiharu YoshiiKatsumi NakatomiGenju KohNobuhiko SekiKeisuke AoeKaname NosakiKoji InoueAyako TakamoriAtsushi Kawaguchi

Published in: Cancer medicine (2021)

NGS of ctDNA could be a promising method for predicting osimertinib efficacy in patients with advanced NSCLC harboring EGFR T790 M.

Keyphrases

advanced non small cell lung cancer
circulating tumor
epidermal growth factor receptor
small cell lung cancer
circulating tumor cells
cell free
tyrosine kinase
end stage renal disease
ejection fraction
peritoneal dialysis
patient reported outcomes
brain metastases
data analysis